I deliver a focused 1–2 page decision memo for one clearly defined biotech question within 48 hours after the scope and source materials are confirmed. The memo is designed for investors, consulting teams, biotech companies, and pharmaceutical teams that need a fast, evidence-based second look before a meeting or decision.
Typical questions include technology or platform claims, cell and gene therapy, mRNA, CRISPR, viral vectors, preclinical strategy, Discovery-to-IND readiness, evidence gaps, and China–U.S. development considerations. I can also review a limited set of scientific claims or presentation slides when the scope is agreed in advance.
The deliverable separates key evidence, critical assumptions, material risks, conflicting signals, unanswered questions, and recommended next checks. One short walkthrough is included.
This service does not provide legal or FTO opinions, medical advice, investment recommendations, regulatory guarantees, academic ghostwriting, or confidential information from former employers or clients.